/PRNewswire/ VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA.
The dengue vaccine industry is on a promising growth trajectory, with an estimated valuation of US$ 474.8 million in 2023. Anticipated demand for dengue vaccines is set to surge, with a projected sales volume CAGR of 12.9%.Dengue vaccine development has reached a pivotal phase in its lifecycle, marked by several pha.
Improved electrospray deposition technique could bring jab-free vaccinations – Physics World physicsworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physicsworld.com Daily Mail and Mail on Sunday newspapers.
According to a Future Market Insights (FMI) report, The Dengue Vaccines Market will expand positively, with a total valuation of US$ 474.8 million expected in 2023. The demand for dengue vaccinations is likely to increase at a CAGR of 12.9% by volume (units).Geographic OverviewLatin America is expected to remain the.